(Hypertension. 2000;36:430.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Troglitazone Reduces Reactive Oxygen Species Generation by Leukocytes and Lipid Peroxidation and Improves Flow-Mediated Vasodilatation in Obese Subjects
From the Diabetes-Endocrinology Center of Western New York, Buffalo, NY.
Correspondence to Paresh Dandona, MD, Director, Diabetes-Endocrinology Center of Western New York, 3 Gates Circle, Buffalo, NY 14209. E-mail pdandona{at}mfhs.edu
Abstract—Because troglitazone has been shown to have antioxidant properties, we investigated whether troglitazone administration to obese subjects causes a reduction in (1) reactive oxygen species (ROS) generation by polymorphonuclear leukocytes (PMNLs) and mononuclear cells (MNCs) and (2) lipid peroxidation as reflected in the plasma concentrations of 9-hydroxyoctadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic acid (13-HODE). Seven obese subjects were given 400 mg/d troglitazone for 4 weeks. Blood samples were obtained before troglitazone administration and at weekly intervals thereafter. Insulin concentrations fell significantly at week 1 and remained low at weeks 2 and 4 (P<0.001). ROS generation by PMNLs fell to 77.6±25.1% of the basal at week 1 and 47.9±41.1% at week 4 (P<0.001). ROS generation by MNCs fell to 59.8±15.7% of the basal at week 1 and 35.1±17.6% at week 4 (P<0.001). 9-HODE and 13-HODE concentrations fell significantly from 787.4±52.4 and 713.1±44.7 pg/mL to 720.4±66.7 (P<0.004) and 675.2±65.0 pg/mL (P<0.01) after 4 weeks, respectively. Postischemic dilatation of the brachial artery was measured by ultrasonography. The mean percent dilatation after forearm ischemia before and after troglitazone was 5.5±3.01% and 8.75±3.37% (P<0.02), respectively. The percent increase in diameter after nitroglycerin was 17.08±1.18% before troglitazone, whereas it was 18.9±1.91% (P<0.02) after troglitazone. We conclude that troglitazone has a potent and rapid biological inhibitory effect on ROS generation by PMNLs and MNCs and that it inhibits lipid peroxidation significantly. These changes are associated with a significant improvement in postischemic flow-mediated vasodilation in the brachial artery over a relatively short period of 4 weeks.
Key Words: troglitazone • antioxidants • vasodilation
This article has been cited by other articles:
 |
|
 |
|
  D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, and S. Taddei Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease Diabetes Care, November 1, 2009; 32(suppl_2): S314 - S321. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Demozay, J.-C. Mas, S. Rocchi, and E. Van Obberghen FALDH Reverses the Deleterious Action of Oxidative Stress Induced by Lipid Peroxidation Product 4-Hydroxynonenal on Insulin Signaling in 3T3-L1 Adipocytes Diabetes, May 1, 2008; 57(5): 1216 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3553 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Agarwal Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy Am J Physiol Renal Physiol, March 1, 2006; 290(3): F600 - F605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yilmaz, N. Bukan, G. Ayvaz, A. Karakoc, F. Toruner, N. Cakir, and M. Arslan The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome Hum. Reprod., December 1, 2005; 20(12): 3333 - 3340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Calkin, J. M. Forbes, C. M. Smith, M. Lassila, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1903 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. McMahon, J. Plutzky, E. Daher, T. Bhattacharyya, G. Grunberger, and M. F. DiCarli Effect of a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist on Myocardial Blood Flow in Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1145 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pagnin, G. Fadini, R. de Toni, A. Tiengo, L. Calo, and A. Avogaro Diabetes Induces p66shc Gene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mohanty, A. Aljada, H. Ghanim, D. Hofmeyer, D. Tripathy, T. Syed, W. Al-Haddad, S. Dhindsa, and P. Dandona Evidence for a Potent Antiinflammatory Effect of Rosiglitazone J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2728 - 2735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonseca, C. Desouza, S. Asnani, and I. Jialal Nontraditional Risk Factors for Cardiovascular Disease in Diabetes Endocr. Rev., February 1, 2004; 25(1): 153 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Dobrian, S. D. Schriver, A. A. Khraibi, and R. L. Prewitt Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity Hypertension, January 1, 2004; 43(1): 48 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Lee and T.-F. Chou Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1650 - H1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1927 - 1939. [Full Text] [PDF]
|
|
|
|
|
|
P. Dandona, A. Aljada, A. Chaudhuri, and A. Bandyopadhyay The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2422 - 2429. [Full Text] [PDF]
|
|
|
|
|
|
G. Paradisi, H. O. Steinberg, M. K. Shepard, G. Hook, and A. D. Baron Troglitazone Therapy Improves Endothelial Function to Near Normal Levels in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin Effect of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Activators on Vascular Remodeling in Endothelin-Dependent Hypertension Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. SATO, M. B. KADIISKA, A. J. GHIO, J. CORBETT, Y. C. FANN, S. M. HOLLAND, R. G. THURMAN, and R. P. MASON In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS FASEB J, November 1, 2002; 16(13): 1713 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. St. John Sutton, M. Rendell, P. Dandona, J. F. Dole, K. Murphy, R. Patwardhan, J. Patel, and M. Freed A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, November 1, 2002; 25(11): 2058 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Arima, K. Kohagura, K. Takeuchi, Y. Taniyama, A. Sugawara, Y. Ikeda, M. Abe, K. Omata, and S. Ito Biphasic Vasodilator Action of Troglitazone on the Renal Microcirculation J. Am. Soc. Nephrol., February 1, 2002; 13(2): 342 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aljada, H. Ghanim, J. Friedman, R. Garg, P. Mohanty, and P. Dandona Troglitazone Reduces the Expression of PPAR{{gamma}} While Stimulating That of PPAR{{alpha}} in Mononuclear Cells in Obese Subjects J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3130 - 3133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aljada, R. Garg, H. Ghanim, P. Mohanty, W. Hamouda, E. Assian, and P. Dandona Nuclear Factor-{{kappa}}B Suppressive and Inhibitor-{{kappa}}B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3250 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dandona, A. Aljada, P. Mohanty, H. Ghanim, W. Hamouda, E. Assian, and S. Ahmad Insulin Inhibits Intranuclear Nuclear Factor {{kappa}}B and Stimulates I{{kappa}}B in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3257 - 3265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona Suppression of Nuclear Factor-{{kappa}}B and Stimulation of Inhibitor {{kappa}}B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1306 - 1312. [Abstract] [Full Text]
|
|